Abstract
This project aims at the synthesis of ruthenium(II) complexes coordinated to the ligands dppf (1,1'-diphenylphosphinoferrocene), dpq (dipyrido[3,2-f: 2',3'-h]quinoxaline), dppz (dipyrido[3,2-a:2 ', 3'-c]phenazine) dpqQX (dipyrido[3,2-f 2', 3'-h]quinoxaline[2,3-b]quinoxaline), dppzBTDZ (dipyrido[3,2-a: 2 ',3'-c]phenazine-10,11-(2,1,3-thiadiazole) and CO (carbonyl) and to study its physicochemical properties by 1H, 13C{1H}, 31P{1H} NMR spectrometry, mass spectrometry , IR, UV-Vis, cyclic voltammetry, differential pulse and X-ray diffraction. We also intend to perform new complexes in vitro cytotoxicity assays on cell lines derived from human tumors of breast cancer, for example: MDA-MB-231 and MCF7, as well as studies of new complexes interact with potential targets biological, e.g., DNA and macromolecules such as BSA, which will help us in understanding the stability / reactivity thereof in biological systems its possible mechanisms of action. The interactions of the new ruthenium complexes with biomolecules will be evaluated by viscosity assays, atomic force microscopy and spectrophotometric and fluorescence titrations. Cytotoxicity assays will be performed in tumor cell lines MDA-MB-231 and MCF7 (breast cancer) and normal L929 (fibroblasts derived from mice).
|